FDA Logo links to FDA home page
Center for Drug Evaluation and Research, U.S. Food and Drug AdministrationU.S. Food and Drug AdministrationCenter for Drug Evaluation and Research
  HHS Logo links to Department of Health and Human Services website

FDA Home Page | CDER Home Page | CDER Site Info | Contact CDER | What's New @ CDER

horizonal rule
CDER Home About CDER Drug Information Regulatory Guidance CDER Calendar Specific Audiences CDER Archives
Powered by Google

 Product Approval Information - Licensing Action

Public Health Service
Food and Drug Administration
1401 Rockville Pike
Rockville, MD 20852-1448

January 2, 2003

Our STN Number: BL 103764/5037

Nancy Del Viscio
Novartis Pharmaceutical Corporation
One Health Plaza
East Hanover, NJ 07936-1080

Dear Ms. Del Viscio:

Your request to supplement your biologics license application for Basiliximab to include the addition of a new single dose 10 mg strength of drug product and an additional supplier of -- mL glass vials for 10 mg and 20 mg strengths, --------------------------------------------------------------------, has been approved.

In addition, your request to provide for the following changes in release testing and specifications that are different from the 20 mg strength have been approved:

  • Replacement of the -------------------------------- test for bacterial endotoxins with the ------------------------------------------------------------ assay as a release test for the drug product;

  • Tightened release specifications in the --------------------------------------------------------------------------------------------------, and --------- assays for 10 mg vials of drug product;

  • Change in standard solutions used to evaluate system suitability for the “assay by ---”, the “assay for byproducts and degradation products by ---”, and the “assay for byproducts and degradation products by ---”; and,

  • · Change in ------------------------------------- of dose points per curve to include more than ---- points.

For the 20 mg strength, the above changes in release testing and specifications can be reported in your annual report (21 CFR 601.12(d)).

Please submit final printed labeling at the time of use and include implementation information on FDA Form 356h. Please provide a PDF-format electronic copy as well as original paper copies (ten for circulars and five for other labels).

Results of ongoing stability studies should be submitted throughout the dating period, as they become available, including the results of stability studies from the first three production lots.

This information will be included in your biologics license application file.

Sincerely yours,

--- signature ---

Keith O. Webber, Ph.D.
Division of Monoclonal Antibodies
Office of Therapeutics Research and Review
Center for Biologics Evaluation and Research

Last Updated: 1/24/2003


Back to Top     Back to Index

Date created: September 25, 2003

horizonal rule